Roxee Medication Guide

Clindamycin

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Capsule Multiple FDA labelers Official label facts Owner quick guide first

Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts

Reference refreshed

Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications

FDA application data refreshed

Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports

Safety data refreshed

Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details

Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC

Illustration placeholder

Clindamycin

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Capsule Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Clindamycin

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci ( Staphylococcus aureus or S. intermedius ), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens . For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci ( Staphylococcus aureus or S. intermedius ), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens . For the treatment of skin infections (wounds and abscesses) due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis, and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, C. perfringens, and B. fragilis . Species commonly shown: Both, Dog, Cat.

Generic name

Clindamycin

Brand names

Antirobe® Capsules, Antirobe Aquadrops®, Clindamycin Hydrochloride Oral Liquid, Clinsol®

Manufacturer

Multiple FDA labelers

Species

Both, Dog, Cat

Dosage forms

Capsule, Liquid (Solution), Tablet, Liquid

Prescription

Prescription required

Completeness

100%

Validation

Complete

Brand names

Antirobe® Capsules Antirobe Aquadrops® Clindamycin Hydrochloride Oral Liquid Clinsol® Clindamycin Hydrochloride Capsules Clintabs® ClindaRobe™ Clindamycin Hydrochloride Oral Drops ClindaMed™ Oral Drops Clindamycin Hydrochloride Tablets Clindamycin Clindamycin Hydrochloride CLINTABS Antirobe Aquadrops Antirobe ZydaClin

Dosage forms

Capsule Liquid (Solution) Tablet Liquid

Indications / Uses

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci ( Staphylococcus aureus or S. intermedius ), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis , Prevotella melaninogenicus , Fusobacterium necrophorum , and Clostridium perfringens , dental infections due to susceptible strains of S. aureus , B. fragilis , P. melaninogenicus , F. necrophorum , and C. perfringens , and osteomyelitis due to susceptible strains of S. aureus , B. fragilis , P. melaninogenicus , F. necrophorum , and C. perfringens . For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci ( Staphylococcus aureus or S. intermedius ), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis , Prevotella melaninogenicus, Fusobacterium necrophorum , and Clostridium perfringens , dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens , and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum , and C. perfringens . For the treatment of skin infections (wounds and abscesses) due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis , and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, C. perfringens , and B. fragilis .

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

Side Effects

Top reported reactions (openFDA): Vomiting, Death by euthanasia, Lethargy (see also Central nervous system depression in 'Neurological'), Anorexia, Other abnormal test result NOS, Lack of efficacy - NOS.

FAQ

Both, Dog, Cat

Yes. Roxee shows this as prescription-only.

Capsule, Liquid (Solution), Tablet, Liquid

Related Conditions

Abscesses (cat bite abscess) Osteomyelitis (infectious)

Source Transparency

Verified source: https://www.roxee.ai/meds/
Verified source: https://animaldrugsatfda.fda.gov
Verified source: https://animaldrugsatfda.fda.gov/adafda/views/#/search
Verified source: https://api.fda.gov/animalandveterinary/event.json
Verified source: https://www.roxee.ai/conditions/
Verified source: https://www.accessdata.fda.gov/spl/data/fa55873a-d841-4757-91ee-3876b64f2e20/fa55873a-d841-4757-91ee-3876b64f2e20.xml
Last refreshed: Aug 6, 2026, 7:47 p.m.
Last verified: Feb 12, 2026, 10:44 p.m.
Validation status: Complete

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

Loss of appetite (1 reports)
Diarrhea (1 reports)
Dermal thickening (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Clindamycin; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2026-US-013066

Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 24 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2026-US-013066

Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2026-US-013066

Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Loss of appetite (1 reports), Diarrhea (1 reports), Dermal thickening (1 reports), Dehydration (1 reports), Decreased cholesterol (1 reports)

Body systems represented Signal grouping

Digestive (3), Skin & allergy (1), Neurologic (2), Behavior (1)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (27 reports), Cat (5 reports)

Breed metadata in reports Metadata only

Domestic Shorthair (5), Schnauzer - Miniature (2), Samoyed (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Clindamycin fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Loss of appetite, Diarrhea, Dermal thickening

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Clindamycin brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.

Vet source depth

openFDA case USA-USFDACVM-2026-US-013066 · adverse_reaction · adverse reactions
Contraindication source · fda_animal_drugs · warnings contraindications
FDA application profile · official_label · quick facts
FDA application profile · official_label · quick facts
Medication usage source · fda_animal_drugs · quick facts
FOI · document · documents
SPL · document · documents
FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:

FDA application profile · official_label
FDA application profile · official_label
Medication usage source · fda_animal_drugs
ClindaMed™ Oral Drops · official_label
openFDA case USA-USFDACVM-2026-US-013066 · adverse_reaction

Safety & side effects

Side effects to monitor:

Loss of appetite
Diarrhea
Dermal thickening

Most reported reactions:

Loss of appetite (1 reports)
Diarrhea (1 reports)
Dermal thickening (1 reports)

Explore reported case details

Emergency warning signs:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species

Cat, Dog

Indication / use

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci ( Staphylococcus aureus or S. intermedius ), deep wounds…

Form / route / dose

Form: Capsule, Liquid, Liquid (Solution), Tablet
Route: Oral
Confirm product label and patient-specific plan.

Warnings

High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug t…

Adverse-event caveat

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Multiple FDA labelers

Form: Capsule, Liquid, Liquid (Solution), Tablet

Identifiers:

ANADA: 200193 ANADA: 200291 ANADA: 200298 ANADA: 200316 ANADA: 200383 ANADA: 200398 ANADA: 200538 ANADA: 200813 NADA: 120161 NADA: 135940 NDC Package: 13985-957-25 NDC Package: 51311-400-40 NDC Package: 51311-402-75 NDC Package: 51311-404-15 NDC Package: 54771-3043-1 NDC Package: 54771-3044-1 NDC Package: 54771-3045-1 NDC Package: 54771-3179-1 NDC Package: 54771-3179-2 NDC Package: 69043-013-20

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200813 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/120161 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Stored reports

Matching reports

Active filters

Species

Breed

Size / weight

Age

Sex

Seriousness

Outcome

Reaction

Body system

Region

Received after

Received before

Reset

Drill into common report signals

Death (5) Lethargy (see also Central nervous system depression in Neurological) (5) Elevated blood urea nitrogen (BUN) (4) Elevated symmetrical dimethylarginine (SDMA) (4) Other (20) Neurologic (10) Digestive (6) Skin & allergy (5)

Showing up to 50 matching reports.

USA-USFDACVM-2026-US-014603

Received 2026-03-18 · MSK · MSK

Non-serious

Species: Dog
Breed: Schnauzer - Miniature
Size / weight: 10-24 lb (7.212 Kilogram)
Age: 8+ years (14 Year)
Sex: Male Neutered
Region: USA
Reactions: AtaxiaCollapse of legElevated blood urea nitrogen (BUN)Elevated cholesterol (total)WeaknessConfusionHyperphosphataemiaElevated symmetrical dimethylarginine (SDMA)Hind limb ataxiaDifficulty standingDifficulty going up/down stairsCircling - neurological disorder (see also Behavioural disorders)
Body systems: NeurologicOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-014257

Received 2026-03-17 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: Under 10 lb (4.53 Kilogram)
Age: 1-3 years (2 Year)
Sex: Female Neutered
Region: USA
Reactions: Limb amputationInjection site sarcomaBehavioural disorder NOSLethargy (see also Central nervous system depression in Neurological)Localised pain NOS (see other SOCs for specific pain)VocalisationLimpingInjection site mass NOS
Body systems: OtherBehaviorNeurologic
Outcomes: Outcome Unknown

USA-USFDACVM-2026-US-014092

Received 2026-03-16 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: Under 10 lb (4.354 Kilogram)
Age: 4-7 years (7 Year)
Sex: Female Neutered
Region: USA
Reactions: DroolingReluctant to moveNot eatingDilated pupilsNot himself/herselfHypothermiaTachypnoeaIntentional misuseLeukopenia NOSHypoglycaemiaElevated symmetrical dimethylarginine (SDMA)AzotaemiaLow ionized calcium (Ca; Hypocalcaemia, ionized)ObtundedWeak pulseLateral recumbencyRegurgitationCardiac arrestDeath
Body systems: DigestiveOther
Outcomes: Died

USA-USFDACVM-2026-US-013313

Received 2026-03-16 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (6.427 Kilogram)
Age: 8+ years (13 Year)
Sex: Female Neutered
Region: USA
Reactions: PruritusSkin lesion NOSSkin scab
Body systems: Skin & allergyOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-013066

Received 2026-03-16 · MSK · MSK

Serious

Species: Dog
Breed: Samoyed
Size / weight: 50-99 lb (24.948 Kilogram)
Age: 8+ years (9 Year)
Sex: Male Neutered
Region: USA
Reactions: Lethargy (see also Central nervous system depression in Neurological)ShakingPale mucous membraneCold feeling of extremityVomitingTachycardiaLaboured breathingTachypnoeaDehydrationWeak pulseTense abdomenHypochloraemiaHyponatremiaAzotaemiaHypocalcaemiaHypoglycaemiaHyperphosphataemiaHypoproteinaemiaHypoalbuminaemiaLow alanine aminotransferase (ALT)Elevated lactateIncreased percentage reticulocytesLymphocytosisMonocytosisAbnormal red blood cellHypotensionAbdominal effusionAspiration pneumoniaHeart murmurGastric perforationLateral recumbencySepticaemiaCoagulopathyHypernatraemiaHypercalcaemiaElevated serum alkaline phosphatase (ALP)NeutrophiliaStridor (Upper respiratory; for lower respiratory see also Bronchial rale)Unresponsive to stimuliCyanotic mucous membranesThrombosisOedema of the extremities (see also other SOCs for most applicable oedema)Pitting oedemaLamenessElevated aspartate aminotransferase (AST)Stertor
Body systems: NeurologicOtherDigestive
Outcomes: Ongoing

USA-USFDACVM-2026-US-012493

Received 2026-03-16 · MSK · MSK

Non-serious

Species: Dog
Breed: Schnauzer - Miniature
Size / weight: 10-24 lb (7.212 Kilogram)
Age: 8+ years (14 Year)
Sex: Male Neutered
Region: USA
Reactions: AtaxiaCollapse of legElevated blood urea nitrogen (BUN)Elevated cholesterol (total)WeaknessConfusionHyperphosphataemiaElevated symmetrical dimethylarginine (SDMA)
Body systems: NeurologicOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-010698

Received 2026-02-24 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (6.427 Kilogram)
Age: 8+ years (13 Year)
Sex: Female Neutered
Region: USA
Reactions: PruritusSkin lesion NOSSkin scabLabeled drug-species interactionIntentional misuse
Body systems: Skin & allergyOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-007430

Received 2026-02-19 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (4.98 Kilogram)
Age: 8+ years (8 Year)
Sex: Female Neutered
Region: USA
Reactions: Dilated pupilsHyperactivityQuiet
Body systems: Other
Outcomes: Ongoing

USA-USFDACVM-2026-US-007170

Received 2026-02-17 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (5.57 Kilogram)
Age: 8+ years (9 Year)
Sex: Male Neutered
Region: USA
Reactions: VomitingWeaknessNot eatingLimb weaknessElevated betahydroxybutyrate (BHBA)Excessive appetiteHyperglycaemia
Body systems: DigestiveOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-005573

Received 2026-01-30 · MSK · MSK

Non-serious

Species: Dog
Breed: ['Retriever - Labrador', 'Chow Chow']
Size / weight: 50-99 lb (24.95 Kilogram)
Age: 4-7 years (5 Year)
Sex: Female Neutered
Region: USA
Reactions: Localised oedema (not application site)WoundSwollen limbLickingLocalised pain NOS (see other SOCs for specific pain)Tooth disorder
Body systems: Other
Outcomes: Ongoing

USA-USFDACVM-2026-US-003714

Received 2026-01-29 · MSK · MSK

Non-serious

Species: Dog
Breed: Schnauzer - Miniature
Size / weight: 10-24 lb (7.212 Kilogram)
Age: 8+ years (14 Year)
Sex: Male Neutered
Region: USA
Reactions: AtaxiaCollapse of legElevated blood urea nitrogen (BUN)Elevated cholesterol (total)WeaknessConfusionHyperphosphataemiaElevated symmetrical dimethylarginine (SDMA)Discomfort NOS
Body systems: NeurologicOther
Outcomes: Ongoing

USA-USFDACVM-2025-US-074897

Received 2025-12-12 · MSK · MSK

Serious

Species: Dog
Breed: ['Chihuahua', 'Dog (unknown)']
Size / weight: Under 10 lb (2.26 Kilogram)
Age: Under 1 year (2 Week)
Sex: Female Intact
Region: USA
Reactions: IcterusDeathOther abnormal test result NOSElevated liver enzymes NOSSwollen jointLocalised hair lossSkin lesion NOSConjunctival oedemaCorneal oedemaSkin scabSwollen limbLethargy (see also Central nervous system depression in Neurological)AnorexiaEar infection NOSLocal swelling (not application site)
Body systems: OtherSkin & allergyNeurologicDigestive
Outcomes: Died

USA-USFDACVM-2025-US-071574

Received 2025-12-05 · MSK · MSK

Serious

Species: Dog
Breed: Spitz - German Pomeranian
Size / weight: Under 10 lb (1.633 Kilogram)
Age: 4-7 years (4 Year)
Sex: Female Neutered
Region: USA
Reactions: Decreased appetiteVomiting bileDiarrhoeaElectrolyte disorderHypoalbuminaemiaDecreased cholesterol (total)Low creatinineWeight loss
Body systems: DigestiveOther
Outcomes: Ongoing

USA-USFDACVM-2025-US-071565

Received 2025-12-03 · MSK · MSK

Serious

Species: Dog
Breed: Dog (unknown)
Size / weight: 25-49 lb (14.969 Kilogram)
Age: 8+ years (15 Year)
Sex: Male Neutered
Region: USA
Reactions: Head tilt - neurological disorder (see also Head tilt - ear disorder)Walking difficultyVomitingSkin and tissue infection NOSGeneral illnessDeath
Body systems: NeurologicOtherDigestive
Outcomes: Died

USA-USFDACVM-2025-US-072712

Received 2025-12-01 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: Under 10 lb (3.175 Kilogram)
Age: 8+ years (15 Year)
Sex: Female Neutered
Region: USA
Reactions: Not eatingHead tilt - ear disorderElevated blood urea nitrogen (BUN)
Body systems: Other
Outcomes: Ongoing

USA-USFDACVM-2025-US-074320

Received 2025-11-24 · MSK · MSK

Serious

Species: Dog
Breed: ['Terrier (unspecified)', 'Dog (unknown)']
Size / weight: 25-49 lb (18.14 Kilogram)
Age: 8+ years (9 Year)
Sex: Male Neutered
Region: USA
Reactions: Behavioural disorder NOSEpidermal collaretteHepatic toxicosisDermal thickeningPyodermaJoint swellingLocal swelling (not application site)Skin ulcerLethargy (see also Central nervous system depression in Neurological)ItchingHair loss NOSDeathInappetence
Body systems: BehaviorOtherSkin & allergyNeurologic
Outcomes: Died

USA-USFDACVM-2025-US-070095

Received 2025-11-22 · MSK · MSK

Serious

Species: Dog
Breed: Terrier - Boston
Size / weight: 25-49 lb (12.247 Kilogram)
Age: 8+ years (11 Year)
Sex: Male Neutered
Region: USA
Reactions: Ear irritationPolypEye inflammation NOSEye irritationAbnormal cytologyScratchingMedication error NOSEar painEar canal inflammationCorneal disorder NOSCorneal oedemaCorneal ulcerIncreased intra-ocular pressure
Body systems: Other
Outcomes: Ongoing

USA-USFDACVM-2025-US-073374

Received 2025-11-17 · MSK · MSK

Serious

Species: Cat
Sex: Male Unknown
Region: USA
Reactions: Neurological symptoms NOS
Body systems: Neurologic
Outcomes: Euthanized

USA-USFDACVM-2025-US-068424

Received 2025-11-17 · MSK · MSK

Serious

Species: Dog
Breed: ['Terrier (unspecified)', 'Dog (unknown)']
Size / weight: 25-49 lb (18.14 Kilogram)
Age: 8+ years (9 Year)
Sex: Male Neutered
Region: USA
Reactions: Behavioural disorder NOSEpidermal collaretteHepatic toxicosisDermal thickeningPyodermaJoint swellingLocal swelling (not application site)Skin ulcerLethargy (see also Central nervous system depression in Neurological)ItchingHair loss NOSDeathInappetence
Body systems: BehaviorOtherSkin & allergyNeurologic
Outcomes: Died

USA-USFDACVM-2025-US-065825

Received 2025-11-05 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Mediumhair
Size / weight: Under 10 lb (3.719 Kilogram)
Age: 8+ years (12 Year)
Sex: Male Neutered
Region: USA
Reactions: Reluctant to moveWobblinessNasal congestionSleepiness - systemic disorderHind limb paralysisThrombosisParalysisDeath by euthanasia
Body systems: Other
Outcomes: Euthanized

USA-USFDACVM-2025-US-063054

Received 2025-10-16 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: Under 10 lb (2.54 Kilogram)
Age: 8+ years (1 Year)
Sex: Female Unknown
Region: USA
Reactions: Lack of efficacy - NOSNon-regenerative anaemia
Body systems: EffectivenessOther
Outcomes: Ongoing

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Grouped by Body System

Digestive (3) · Loss of appetite, Diarrhea, Decreased appetite Skin & allergy (1) · Application site hair loss Neurologic (2) · Unsteady walking (ataxia), Circling - neurological disorder Behavior (1) · Behavioral disorder (unspecified) Other (25) · Difficulty standing, Difficulty going up/down stairs, Dermal thickening

Most Reported Reactions

Body system	Cases	Species	Serious cases
Digestive	1	Dog	1
Digestive	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1
Digestive	1	Dog	1
Other	1	Cat	1
Other	1	Dog	1

Species coverage: Dog (27) Cat (5)

View detailed reaction table

Body system	Species	Seriousness	Frequency	Reports
Neurologic	Dog	Non-serious	-	1
Digestive	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Non-serious	-	1
Digestive	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Neurologic	Dog	Non-serious	-	1
Other	Cat	Serious	-	1
Behavior	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Skin & allergy	Cat	Non-serious	-	1
Other	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2026-US-013066

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Clindamycin Hydrochloride Tablets SPL · SPL Antirobe® Capsules SPL · SPL ClindaMed™ Oral Drops SPL · SPL

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

No owner handouts linked yet.

Official label / PI

No official label or package insert links yet.

SPL

FOI

Clindamycin Hydrochloride Tablets

SPL · SPL

Open original

FDA Structured Product Label

Clindamycin Hydrochloride Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Felix Pharmaceuticals Pvt. Ltd.
ANADA: 200-813
Status: RX
Form: Tablet
Route: Oral

Composition / specifications

25 mg, 75 mg, and 150 mg

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Wounds, abscesses, and dental infections: 2.5 to 15 mg per pound (/lb) body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 to 15 mg/lb body weight every 12 hours for a minimum of 28 days.

Antirobe® Capsules

SPL · SPL

Open original

FDA Structured Product Label

Antirobe® Capsules

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 120-161
Status: RX
Form: Capsule
Route: Oral
Species: Dog

Composition / specifications

Each capsule contains the equivalent of 25, 75, 150 or 300 milligrams of clindamycin as the hydrated hydrochloride salt.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Wounds, abscesses, and dental infections: 2.5 to 15 milligrams per pound of body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 to 15 milligrams per pound of body weight every 12 hours for a minimum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ClindaMed™ Oral Drops

SPL · SPL

Open original

FDA Structured Product Label

ClindaMed™ Oral Drops

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Bimeda Animal Health Ltd.
ANADA: 200-538
Status: RX
Form: Liquid
Route: Oral
Species: Dog • Cat

Composition / specifications

Each mL contains clindamycin hydrochloride equivalent to 25 mg clindamycin.

Dogs

Indication

For the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

Skin infections (wounds and abscesses) due to coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius). Deep wounds and abscesses due to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Dosage

Wounds, abscesses, and dental infections: 2.5 to 15 mg per pound body weight every 12 hours for a maximum of 28 days.

Osteomyelitis: 5.0 to 15 mg/lb body weight every 12 hours for a minimum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian

Cats

Indication

Skin infections (wounds and abscesses) due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp. Deep wounds and abscesses due to Clostridium perfringens and Bacteroides fragilis.

Dental infections due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens and Bacteroides fragilis.

Dosage

5.0 to 15.0 mg/lb body weight every 24 hours for a maximum of 14 days

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian

Clindamycin Hydrochloride Oral Drops

SPL · SPL

Open original

FDA Structured Product Label

Clindamycin Hydrochloride Oral Drops

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: First Priority, Inc.
ANADA: 200-398
Status: RX
Form: Liquid (Solution)
Route: Oral
Species: Dog • Cat

Composition / specifications

Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

Dogs

Indication

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis, and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, C. perfringens, and B. fragilis

Dosage

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Antirobe Aquadrops®

SPL · SPL

Open original

FDA Structured Product Label

Antirobe Aquadrops®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 135-940
Status: RX
Form: Liquid (Solution)
Route: Oral
Species: Dog • Cat

Composition / specifications

Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis, and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, C. perfringens, and B. fragilis.

Dosage

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clindamycin Hydrochloride Oral Liquid

SPL · SPL

Open original

FDA Structured Product Label

Clindamycin Hydrochloride Oral Liquid

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Cronus Pharma Specialities India Private Ltd.
ANADA: 200-193
Status: RX
Form: Liquid (Solution)
Route: Oral
Species: Dog • Cat

Composition / specifications

Each milliliter of 8.64 percent alcoholic solution contains the equivalent of 25 milligrams of clindamycin (as the hydrochloride).

Cats

Indication

Aerobic bacteria: Treatment of soft tissue infections (wounds and abscesses) and dental infections caused by or associated with susceptible strains of Staphylococcus aureus, S. intermedius, and Streptococcus species Anaerobic bacteria: Treatment of soft tissue infections (deep wounds and abscesses) and dental infections caused by or associated with susceptible strains of Clostridium perfringens and Bacteroides fragilis.

Dosage

5.0 to 10.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days (11 to 22 milligrams per kilogram of body weight per day).

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs

Indication

For treatment of osteomyelitis caused by susceptible strains of Staphylococcus aureus, and osteomyelitis caused by or associated with susceptible strains of Bacteroides fragilis, Bacteroides melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens.

Dosage

Osteomyelitis: 5.0 milligrams per pound of body weight every 12 hours for a minimum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indication

For use in dogs for treatment of soft tissue infections (wounds and abscesses) and dental infections caused by susceptible strains of Staphylococcus aureus and for soft tissue infections (deep wounds and abscesses) and dental infections caused by or associated with susceptible strains of Bacteroides fragilis, Bacteroides melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens.

Dosage

Wounds abscesses, and dental infections: 2.5 milligrams per pound of body weight every 12 hours for a maximum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clindamycin Hydrochloride Capsules

SPL · SPL

Open original

FDA Structured Product Label

Clindamycin Hydrochloride Capsules

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Cronus Pharma Specialities India Private Ltd.
ANADA: 200-298
Status: RX
Form: Capsule
Route: Oral
Species: Dog

Composition / specifications

Each capsule contains the equivalent of 25, 75, or 150 milligrams of clindamycin as the hydrated hydrochloride salt.

Dogs

Indication

Dosage

Wounds, abscesses, and dental infections: 2.5 milligrams per pound of body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 milligrams per pound of body weight every 12 hours for a minimum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ClindaRobe™

SPL · SPL

Open original

FDA Structured Product Label

ClindaRobe™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Teva Canada Ltd.
ANADA: 200-383
Status: RX
Form: Capsule
Route: Oral
Species: Dog

Composition / specifications

<span style="font-size: 10.5pt; font-family: Verdana; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'">Each capsule contains the equivalent of 25, 75, or 150 mg of clindamycin.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clinsol®

SPL · SPL

Open original

FDA Structured Product Label

Clinsol®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Virbac AH, Inc.
ANADA: 200-291
Status: RX
Form: Liquid (Solution)
Route: Oral
Species: Dog • Cat

Composition / specifications

Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or (S. intermedius), deep wounds and abscesses due to susceptible strains of (Bacteroides fragilis, (Prevotella melaninogenicus, (Fusobacterium necrophorum, and (Clostridium perfringens; dental infections due to susceptible strains of (S. aureus, (B. fragilis, (P. melaninogenicus, (F. necrophorum, and (C. perfringens; and osteomyelitis due to susceptible strains of (S. aureus, (B. fragilis, (P. melaninogenicus, (F. necrophorum, and (C. perfringens.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of Staphylococcus aureus, S. intermedius, Streptococcus spp.; deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis; and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus spp., C. perfringens, and B. fragilis.

Dosage

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Clintabs®

SPL · SPL

Open original

FDA Structured Product Label

Clintabs®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Virbac AH, Inc.
ANADA: 200-316
Status: RX
Form: Tablet
Route: Oral
Species: Dog

Composition / specifications

Each tablet contains the equivalent of 25, 75 or 150 milligrams of clindamycin as the hydrochloride salt.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17171 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/17488/Clindamycin%20Hydrochloride%20Tablets · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/380 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1741/Antirobe%C2%AE%20Capsules · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1226 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1777/ClindaMed%E2%84%A2%20Oral%20Drops · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1143 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/210/Clindamycin%20Hydrochloride%20Oral%20Drops · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/411 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/412 · document · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: Antirobe Antirobe Aquadrops CLINTABS Clindamycin Clindamycin Hydrochloride ZydaClin

Manufacturer mapping: Multiple FDA labelers

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Cat, Dog

Rx/OTC: RX

Form/route: Capsule, Liquid, Liquid (Solution), Tablet • Oral

Applications: ANADA 200-813 • NADA 120-161 • ANADA 200-538 • ANADA 200-398 • NADA 135-940 • ANADA 200-193 • ANADA 200-298 • ANADA 200-383 • ANADA 200-291 • ANADA 200-316

NDC: Packages 13985-957-25 51311-400-40 51311-402-75 51311-404-15 54771-3043-1 54771-3044-1 • Products 13985 51311 54771 69043 86101 86136

Documents: 15 (FOI: 15) • SPL: 10 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 110 • Cat 51 • View

Case summaries: 21 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Abscesses (cat bite abscess) Osteomyelitis (infectious)

Linked using: Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian (Contraindication, High)

Top reaction signals

Loss of appetite (1) Diarrhea (1) Dermal thickening (1) Dehydration (1) Decreased cholesterol (1) Decreased appetite (1) Death by euthanasia (1) Death (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
13985-957-25	13985	-
51311-400-40	51311	-
51311-402-75	51311	-
51311-404-15	51311	-
54771-3043-1	54771	-
54771-3044-1	54771	-
54771-3045-1	54771	-
54771-3179-1	54771	-
54771-3179-2	54771	-
69043-013-20	69043	-
69043-014-20	69043	-
69043-015-01	69043	-
69043-015-05	69043	-
69043-016-01	69043	-
86101-052-18	86101	-
86101-053-15	86101	-
86101-054-11	86101	-
86136-147-03	86136	-
86136-148-03	86136	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Clindamycin Hydrochloride SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Clindamycin Hydrochloride SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
CLINTABS SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Antirobe SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Antirobe Aquadrops SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
ZydaClin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Clindamycin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
FOI Summary oA 200-813 Approved June 27, 2025.pdf • FOI summary • Official • July 1, 2025
FDA FOI summary for application 200813
ucm069817.pdf • FOI summary • Official • Dec. 10, 2019
FDA FOI summary for application 120161
UCM355629.pdf • FOI summary • Official • Oct. 2, 2018
FDA FOI summary for application 200538
ucm061348.pdf • FOI summary • Official • Dec. 27, 2017
FDA FOI summary for application 200398
N135940_Supp_11_16_89(2).pdf • FOI summary • Official • July 11, 2017
FDA FOI summary for application 135940
UCM454278.pdf • FOI summary • Official • July 11, 2017
FDA FOI summary for application 135940
ucm069874.pdf • FOI summary • Official • July 11, 2017
FDA FOI summary for application 135940
A200193_Org_8_1_1997.pdf • FOI summary • Official • May 22, 2017
FDA FOI summary for application 200193
UCM061609.pdf • FOI summary • Official • May 22, 2017
FDA FOI summary for application 200193
UCM061610.pdf • FOI summary • Official • May 22, 2017
FDA FOI summary for application 200193
ucm061338.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200383
ucm061770.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200316
ucm061742.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200298
ucm061743.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200298
ucm061719.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200291

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 141 Clinical 1 Manufacturer 0 Marketing 0

Current Field Facts

side_effects: Top reported reactions (openFDA): Vomiting, Death by euthanasia, Lethargy (see also Central nervous system depression in 'Neurological'), Anorexia, Other abnor… (Clinical, 2026-04-11)
contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Official, 2026-04-12)
contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Official, 2026-04-11)
contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Official, 2026-02-12)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-08-06)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-08-05)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-08-04)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-08-03)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-08-02)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-08-01)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-07-31)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-07-30)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-07-29)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-07-28)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-07-27)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-07-26)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-07-25)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-07-25)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-07-22)
indications: CLINDAROBE Capsules is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions list… (Official, 2026-07-22)

Recent Revisions

side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
Clindamycin Hydrochloride Tablets RX Clindamycin Hydrochloride Tablet • Oral Label highlights Official documents	Felix Pharmaceuticals Pvt. Ltd.	ANADA 200-813	Approved	Jul 1, 2025
Antirobe® Capsules RX Clindamycin Hydrochloride Capsule • Oral Label highlights Official documents	Zoetis Inc.	NADA 120-161	Approved	Dec 10, 2019
ClindaMed™ Oral Drops RX Clindamycin Liquid • Oral Label highlights Official documents	Bimeda Animal Health Ltd.	ANADA 200-538	Approved	Oct 2, 2018
Clindamycin Hydrochloride Oral Drops RX Clindamycin Hydrochloride Liquid (Solution) • Oral Label highlights Official documents	First Priority, Inc.	ANADA 200-398	Approved	Dec 27, 2017
Antirobe Aquadrops® RX Clindamycin Hydrochloride Liquid (Solution) • Oral Label highlights Official documents	Zoetis Inc.	NADA 135-940	Approved	Jul 11, 2017
Clindamycin Hydrochloride Oral Liquid RX Clindamycin Hydrochloride Liquid (Solution) • Oral Label highlights Official documents	Cronus Pharma Specialities India Private Ltd.	ANADA 200-193	Approved	May 22, 2017
Clindamycin Hydrochloride Capsules RX Clindamycin Hydrochloride Capsule • Oral Label highlights Official documents	Cronus Pharma Specialities India Private Ltd.	ANADA 200-298	Approved	Jun 1, 2016
ClindaRobe™ RX Clindamycin Hydrochloride Capsule • Oral Label highlights Official documents	Teva Canada Ltd.	ANADA 200-383	W	Jun 1, 2016
Clinsol® RX Clindamycin Hydrochloride Liquid (Solution) • Oral Label highlights Official documents	Virbac AH, Inc.	ANADA 200-291	Approved	Jun 1, 2016
Clintabs® RX Clindamycin Hydrochloride Tablet • Oral Label highlights Official documents	Virbac AH, Inc.	ANADA 200-316	Approved	Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications

25 mg, 75 mg, and 150 mg

Dogs

Indication

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

Each capsule contains the equivalent of 25, 75, 150 or 300 milligrams of clindamycin as the hydrated hydrochloride salt.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat

Composition / specifications

Each mL contains clindamycin hydrochloride equivalent to 25 mg clindamycin.

Dogs

Indication

For the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Dosage

Wounds, abscesses, and dental infections: 2.5 to 15 mg per pound body weight every 12 hours for a maximum of 28 days.

Osteomyelitis: 5.0 to 15 mg/lb body weight every 12 hours for a minimum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian

Cats

Indication

Dental infections due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens and Bacteroides fragilis.

Dosage

5.0 to 15.0 mg/lb body weight every 24 hours for a maximum of 14 days

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat

Composition / specifications

Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

Dogs

Indication

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

Dosage

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat

Composition / specifications

Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

Dosage

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat

Composition / specifications

Each milliliter of 8.64 percent alcoholic solution contains the equivalent of 25 milligrams of clindamycin (as the hydrochloride).

Cats

Indication

Dosage

5.0 to 10.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days (11 to 22 milligrams per kilogram of body weight per day).

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs

Indication

Dosage

Osteomyelitis: 5.0 milligrams per pound of body weight every 12 hours for a minimum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indication

Dosage

Wounds abscesses, and dental infections: 2.5 milligrams per pound of body weight every 12 hours for a maximum of 28 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

Each capsule contains the equivalent of 25, 75, or 150 milligrams of clindamycin as the hydrated hydrochloride salt.

Dogs

Indication

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

Dogs

Indication

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens, and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens.

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat

Composition / specifications

Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

Dogs

Indication

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats

Indication

Dosage

5.0 to 15.0 milligrams per pound of body weight every 24 hours for a maximum of 14 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

Each tablet contains the equivalent of 25, 75 or 150 milligrams of clindamycin as the hydrochloride salt.

Dogs

Indication

Dosage

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci ( Staphylococcus aureus or S. intermedius ), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis , Prevotella melaninogenicus , Fusobacterium necrophorum , and Clostridium perfringens , dental infections due to susceptible strains of S. aureus , B. fragilis , P. melaninogenicus , F. necrophorum , and C. perfringens , and osteomyelitis due to susceptible strains of S. aureus , B. fragilis , P. melaninogenicus , F. necrophorum , and C. perfringens . For the treatment of skin infections (wounds and abscesses) due to susceptible strains of coagulase-positive staphylococci ( Staphylococcus aureus or S. intermedius ), deep wounds and abscesses due to susceptible strains of Bacteroides fragilis , Prevotella melaninogenicus, Fusobacterium necrophorum , and Clostridium perfringens , dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum, and C. perfringens , and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenicus, F. necrophorum , and C. perfringens . For the treatment of skin infections (wounds and abscesses) due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis , and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus species, C. perfringens , and B. fragilis .

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive

Loss of appetite (1) • Dog Diarrhea (1) • Dog Decreased appetite (1) • Dog

Showing top 5 for Digestive.

Skin & allergy

Application site hair loss (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic

Unsteady walking (1) • Dog Circling - neurological disorder (1) • Dog

Showing top 5 for Neurologic.

Behavior

Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Other

Difficulty standing (1) • Dog Difficulty going up/down stairs (1) • Dog Dermal thickening (1) • Dog Dehydration (1) • Dog Decreased cholesterol (1) • Dog

Show more (20)

Death by euthanasia (1) • Cat Death (1) • Dog Cyanotic mucous membranes (1) • Dog Corneal ulcer (1) • Dog Corneal oedema (1) • Dog Corneal disorder NOS (1) • Dog Conjunctival oedema (1) • Dog Confusion (1) • Dog Collapse of leg (1) • Dog Collapse NOS (1) • Dog Cold feeling of extremity (1) • Dog Coagulopathy (1) • Dog Cardiac arrest (1) • Cat Azotaemia (1) • Dog Aspiration pneumonia (1) • Dog Application site excoriation (1) • Cat Abnormal red blood cell (1) • Dog Abnormal menace reflex test (1) • Dog Abnormal cytology (1) • Dog Abdominal effusion (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Schnauzer - Miniature, Male, 14 year, 7.212 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Unsteady walking (ataxia), Collapse of leg, Elevated blood urea nitrogen, Elevated cholesterol, Weakness… • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-014603
Serious AE: No
Treated For AE: No
Sex: Male
Age: 14.00 Year
Weight: 7.212 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Unassigned

Reactions Reported:

Unsteady walking (ataxia) Collapse of leg Elevated blood urea nitrogen Elevated cholesterol Weakness Confusion Hyperphosphataemia Elevated symmetrical dimethylarginine Hind limb ataxia Difficulty standing Difficulty going up/down stairs Circling - neurological disorder

Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 2 year, 4.53 kilogram • Drug: MSK, Unknown • Reactions: Limb amputation, Injection site sarcoma, Behavioral disorder (unspecified), Tiredness (lethargy), Localised pain NOS… • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2026-US-014257
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 2.00 Year
Weight: 4.530 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Limb amputation Injection site sarcoma Behavioral disorder (unspecified) Tiredness (lethargy) Localised pain NOS Vocalisation Limping Injection site mass NOS

Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Female, 7 year, 4.354 kilogram • Drug: MSK, Solution/drops, Oral • Reactions: Drooling, Reluctant to move, Not eating, Dilated pupils, Not himself/herself… • Outcome: Died

Report ID: USA-USFDACVM-2026-US-014092
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 7.00 Year
Weight: 4.354 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Solution/drops

Reactions Reported:

Drooling Reluctant to move Not eating Dilated pupils Not himself/herself Hypothermia Tachypnoea Intentional misuse Leukopenia NOS Hypoglycaemia Elevated symmetrical dimethylarginine Azotaemia Low ionized calcium Obtunded Weak pulse Lateral recumbency Regurgitation Cardiac arrest Death

Outcomes: Died

Cat, Domestic Shorthair, Female, 13 year, 6.427 kilogram • Drug: MSK, Unknown • Reactions: Itching, Skin lesion NOS, Skin scab • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-013313
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 13.00 Year
Weight: 6.427 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Itching Skin lesion NOS Skin scab

Outcomes: Ongoing

Dog, Samoyed, Male, 9 year, 24.948 kilogram • Drug: MSK, Oral • Reactions: Tiredness (lethargy), Shaking, Pale mucous membrane, Cold feeling of extremity, Vomiting… • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-013066
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 9.00 Year
Weight: 24.948 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral

Reactions Reported:

Tiredness (lethargy) Shaking Pale mucous membrane Cold feeling of extremity Vomiting Tachycardia Laboured breathing Tachypnoea Dehydration Weak pulse Tense abdomen Hypochloraemia Hyponatremia Azotaemia Hypocalcaemia Hypoglycaemia Hyperphosphataemia Hypoproteinaemia Hypoalbuminaemia Low alanine aminotransferase Elevated lactate Increased percentage reticulocytes Lymphocytosis Monocytosis Abnormal red blood cell Hypotension Abdominal effusion Aspiration pneumonia Heart murmur Gastric perforation Lateral recumbency Septicaemia Coagulopathy Hypernatraemia Hypercalcaemia Elevated serum alkaline phosphatase Neutrophilia Stridor Unresponsive to stimuli Cyanotic mucous membranes Thrombosis Oedema of the extremities Pitting oedema Lameness Elevated aspartate aminotransferase Stertor

Outcomes: Ongoing

Dog, Schnauzer - Miniature, Male, 14 year, 7.212 kilogram • Drug: MSK, Solution/drops, Unknown • Reactions: Unsteady walking (ataxia), Collapse of leg, Elevated blood urea nitrogen, Elevated cholesterol, Weakness… • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-012493
Serious AE: No
Treated For AE: No
Sex: Male
Age: 14.00 Year
Weight: 7.212 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Solution/drops

Reactions Reported:

Unsteady walking (ataxia) Collapse of leg Elevated blood urea nitrogen Elevated cholesterol Weakness Confusion Hyperphosphataemia Elevated symmetrical dimethylarginine

Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 13 year, 6.427 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Itching, Skin lesion NOS, Skin scab, Labeled drug-species interaction, Intentional misuse • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-010698
Serious AE: No
Treated For AE: Yes
Sex: Female
Age: 13.00 Year
Weight: 6.427 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Unassigned

Reactions Reported:

Itching Skin lesion NOS Skin scab Labeled drug-species interaction Intentional misuse

Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 8 year, 4.98 kilogram • Drug: MSK, Unknown • Reactions: Dilated pupils, Hyperactivity, Quiet • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-007430
Serious AE: No
Treated For AE: Yes
Sex: Female
Age: 8.00 Year
Weight: 4.980 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Dilated pupils Hyperactivity Quiet

Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on Roxee are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Clindamycin

Data freshness

Clindamycin

Medication Snapshot

Clindamycin

Indications / Uses

Warnings / Contraindications

Side Effects

FAQ

What species is this commonly shown for?

Does this usually require a prescription?

What dosage forms are listed?

Related Conditions

Source Transparency

Add to My Pet's Medications

Pet Owner Quick Guide

Next actions

Medication Research Insights

What to know

Evidence tension

Reaction signal map

Species and breed lens

What your vet may verify

What to watch next

Evidence

Vet Fast Scan

Quick Facts

Warnings / Contraindications

Adverse Reactions

Reported case explorer

USA-USFDACVM-2026-US-014603

USA-USFDACVM-2026-US-014257

USA-USFDACVM-2026-US-014092

USA-USFDACVM-2026-US-013313

USA-USFDACVM-2026-US-013066

USA-USFDACVM-2026-US-012493

USA-USFDACVM-2026-US-010698

USA-USFDACVM-2026-US-007430

USA-USFDACVM-2026-US-007170

USA-USFDACVM-2026-US-005573

USA-USFDACVM-2026-US-003714

USA-USFDACVM-2025-US-074897

USA-USFDACVM-2025-US-071574

USA-USFDACVM-2025-US-071565

USA-USFDACVM-2025-US-072712

USA-USFDACVM-2025-US-074320

USA-USFDACVM-2025-US-070095

USA-USFDACVM-2025-US-073374

USA-USFDACVM-2025-US-068424

USA-USFDACVM-2025-US-065825

USA-USFDACVM-2025-US-063054

Grouped by Body System

Most Reported Reactions

Source Documents

Owner handouts

Official label / PI

SPL

FOI

Clindamycin Hydrochloride Tablets

Clindamycin Hydrochloride Tablets

Dogs

Antirobe® Capsules

Antirobe® Capsules

Dogs

ClindaMed™ Oral Drops

ClindaMed™ Oral Drops

<strong>Dogs</strong>

<strong>Cats</strong>

Clindamycin Hydrochloride Oral Drops

Clindamycin Hydrochloride Oral Drops

Dogs

Cats

Antirobe Aquadrops®

Antirobe Aquadrops®

Dogs

Cats

Clindamycin Hydrochloride Oral Liquid

Clindamycin Hydrochloride Oral Liquid

Cats

Dogs